Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

Shelley Wood

October 29, 2017

News Daily News

Severe Aortic Stenosis Gets Its Own Appropriate Use Criteria

Caitlin E. Cox

October 18, 2017

News Daily News

Excluded From Trials, Patients With Severe Kidney Disease Benefit Less From TAVR

Shelley Wood

October 10, 2017

News Daily News

Asymptomatic Carotid Artery Stenosis: When to Screen and When to Intervene

Todd Neale

October 05, 2017

News Conference News PCR London Valves 2017

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

Shelley Wood

September 24, 2017

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Shelley Wood

August 27, 2017

News Daily News

TAVR in the US: Regional Variations in Numbers, Outcomes

Michael O'Riordan

August 22, 2017

Studies Supporting Device Modifications Weak, Often Based on Surrogate Endpoints

News Daily News

FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints

Michael O'Riordan

August 16, 2017

News Daily News

Identifying CAD in Stable Patients: CT Imaging or Start With Functional Testing?

Yael L. Maxwell

July 12, 2017

News Conference News SCCT 2017

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

Yael L. Maxwell

July 10, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Michael O'Riordan

June 16, 2017

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Daily News

Comrades in TAVR? Cardiac Surgeons Say They’re Involved in All Stages of TAVR Care

Yael L. Maxwell

April 14, 2017

News Features

Living or Leaving: Does Palliative Care Deserve a Place at the TAVR Table?

Caitlin E. Cox

March 31, 2017

News Daily News

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Todd Neale

March 22, 2017

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

Advertisement

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

TCTMD’s Top 10 Most Popular Stories for October 2017

Severe Aortic Stenosis Gets Its Own Appropriate Use Criteria

Excluded From Trials, Patients With Severe Kidney Disease Benefit Less From TAVR

Asymptomatic Carotid Artery Stenosis: When to Screen and When to Intervene

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

TAVR in the US: Regional Variations in Numbers, Outcomes

FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints

Identifying CAD in Stable Patients: CT Imaging or Start With Functional Testing?

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Comrades in TAVR? Cardiac Surgeons Say They’re Involved in All Stages of TAVR Care

Living or Leaving: Does Palliative Care Deserve a Place at the TAVR Table?

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content